Rola F. Jaafar

Dr. Rola F. Jaafar

IARC/WHO, Lyon, Auvergne-Rhône-Alpes, France
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MZMaroun Bou Zerdan
Maroun Bou Zerdan
TGTala Ghorayeb
Tala Ghorayeb
FSFares Saliba
Fares Saliba
SASabine Allam
Sabine Allam
MZMorgan Bou Zerdan
Morgan Bou Zerdan
ZNZeina Nahleh
Zeina Nahleh
Breast cancer (BC) is the most common malignancy affecting women. It is a highly heterogeneous disease broadly defined by the differential expression of cell surface receptors. In the United States, triple negative breast cancer (TNBC) represents 15 to 20% of all BC. When compared with other subtypes of BC, TNBC tends to present in younger women, and has a higher mortality rate of 40% in advanced stages within the first 5 years after diagnosis. TNBC has historically had limited treatment options when compared to other types of BC. The mainstay of treatment for TNBC remains cytotoxic chemotherapy despite the emergence of new biologic and targeted agents. Defining the specific tumor molecular profile including PDL-1 and androgen receptor testing is expanding treatment options in the clinical setting. Identifying more targetable, novel biomarkers that may better define therapeutic targets or prognostic markers is currently underway. TNBC nomenclature is expected to be updated in favor of other nomenclature which would help direct therapy, and further redefine TNBC’s heterogeneity. Given the continuous advances in the field of TNBC, this review assesses the latest developments in basic characterization, subtyping, and treatment of TNBC, including novel drug developments with antibody-drug conjugates, immune checkpoint inhibitors, PARP inhibitors and androgen receptor targeted agents. Future trials are necessary in the face of these innovations to further support the use of new therapies in TNBC and the detection of the appropriate biomarkers.

1 February 2008 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ZBZiad F. Bashshur
Ziad F. Bashshur
ZHZeina A. Haddad
Zeina A. Haddad
ASAlexandre Schakal
Alexandre Schakal
RJRola F. Jaafar
Rola F. Jaafar
MSMarc Saab
Marc Saab
BNBaha’ N. Noureddin
Baha’ N. Noureddin

1 August 2017 in The Lancet Respiratory Medicine
Verified
Journal Article
Open access
FMFabiana Madotto
Fabiana Madotto
GBGiacomo Bellani
Giacomo Bellani
EFEddy Fan
Eddy Fan
LBLaurent Brochard
Laurent Brochard
PAPravin Amin
Pravin Amin
MVMilic Veljovic
Milic Veljovic
Little information is available about the geo-economic variations in demographics, management, and outcomes of patients with acute respiratory distress syndrome (ARDS). We aimed to characterise the effect of these geo-economic variations in patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE). LUNG SAFE was done during 4 consecutive weeks in winter, 2014, in a convenience sample of 459 intensive-care units in 50 countries across six continents. Inclusion criteria were admission to a participating intensive-care unit (including transfers) within the enrolment window and receipt of invasive or non-invasive ventilation. One of the trial's secondary aims was to characterise variations in the demographics, management, and outcome of patients with ARDS. We used the 2016 World Bank countries classification to define three major geo-economic groupings, namely European high-income countries (Europe-High), high-income countries in the rest of the world (rWORLD-High), and middle-income countries (Middle). We compared patient outcomes across these three groupings. LUNG SAFE is registered with ClinicalTrials.gov, number NCT02010073. Of the 2813 patients enrolled in LUNG SAFE who fulfilled ARDS criteria on day 1 or 2, 1521 (54%) were recruited from Europe-High, 746 (27%) from rWORLD-High, and 546 (19%) from Middle countries. We noted significant geographical variations in demographics, risk factors for ARDS, and comorbid diseases. The proportion of patients with severe ARDS or with ratios of the partial pressure of arterial oxygen (PaO2) to the fractional concentration of oxygen in inspired air (FiO2) less than 150 was significantly lower in rWORLD-High countries than in the two other regions. Use of prone positioning and neuromuscular blockade was significantly more common in Europe-High countries than in the other two regions. Adjusted duration of invasive mechanical ventilation and length of stay in the intensive-care unit were significantly shorter in patients in rWORLD-High countries than in Europe-High or Middle countries. High gross national income per person was associated with increased survival in ARDS; hospital survival was significantly lower in Middle countries than in Europe-High or rWORLD-High countries. Important geo-economic differences exist in the severity, clinician recognition, and management of ARDS, and in patients' outcomes. Income per person and outcomes in ARDS are independently associated. European Society of Intensive Care Medicine, St Michael's Hospital, University of Milan-Bicocca.

1 December 2008 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
MKMireille M. Kattar
Mireille M. Kattar
RJRola F. Jaafar
Rola F. Jaafar
GAGeorge F. Araj
George F. Araj
PFPhilippe Le FlècHe
Philippe Le FlècHe
GMGhassan M. Matar
Ghassan M. Matar
Gilles VergnaudGilles Vergnaud
Gilles Vergnaud
Brucellosis remains an important anthropozoonosis worldwide. Brucella species are genetically homogeneous, and thus, the typing of Brucella species for epidemiological purposes by conventional molecular typing methods has remained elusive. Although many methods could segregate isolates into the phylogenetically recognized taxa, limited within-species genetic diversity has been identified. Recently, multilocus variable-number tandem-repeat analysis (MLVA) was found to have a high degree of resolution when it was applied to collections of Brucella isolates from geographically widespread locations, and an assay comprising 16 such loci (MLVA-16) was proposed. This scheme includes eight minisatellite loci (panel 1) and eight microsatellites (panel 2, which is subdivided into panels 2A and 2B). The utility of MLVA-16 for the subtyping of human Brucella isolates from geographically restricted regions needs to be further evaluated, and genotyping databases with worldwide coverage must be progressively established. In the present study, MLVA-16 was applied to the typing of 42 human Brucella isolates obtained from 41 patients recovered from 2002 to 2006 at a tertiary-care center in Lebanon. All isolates were identified as Brucella melitensis by MLVA-16 and were found to be closely related to B. melitensis isolates from neighboring countries in the Middle East when their genotypes were queried against those in the web-based Brucella2007 MLVA database ( http://mlva.u-psud.fr/ ). Panel 2B, which comprised the most variable loci, displayed a very high discriminatory power, while panels 1 and 2A showed limited diversity. The most frequent genotype comprised seven isolates obtained over 7 weeks in 2002, demonstrating an outbreak from a common source. Two isolates obtained from one patient 5 months apart comprised another genotype, indicating relapsing disease. These findings confirm that MLVA-16 has a good discriminatory power for species determination, typing of B. melitensis isolates, and inferring their geographical origin. Abbreviated panel 2B could be used as a short-term epidemiological tool in a small region of endemicity.

1 July 2009 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ZBZiad F. Bashshur
Ziad F. Bashshur
ZHZeina A. Haddad
Zeina A. Haddad
ASAlexandre R. Schakal
Alexandre R. Schakal
RJRola F. Jaafar
Rola F. Jaafar
ASAlain Saad
Alain Saad
BNBaha' N. Noureddin
Baha' N. Noureddin

1 October 2007 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
ZBZiad F. Bashshur
Ziad F. Bashshur
ASAlexandre Schakal
Alexandre Schakal
RHRola N. Hamam
Rola N. Hamam
CHChristelle P. El Haibi
Christelle P. El Haibi
RJRola F. Jaafar
Rola F. Jaafar
BNBaha’ N. Noureddin
Baha’ N. Noureddin
Research from JAMA Ophthalmology — Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration